GenScript now offers fast-track cGMP neoantigen peptide and peptide active pharmaceutical ingredients (API) from its new life-sciences manufacturing facility in Zhenjiang, leveraging its long history ...
GenScript Biotech Corp. has expanded its research capabilities overseas with a new life sciences facility in China, the Piscataway-headquartered company announced May 18. Located in the city of ...
Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...
GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...
GenScript can synthesize numerous difficult neoantigen peptides and offer specialized optimization tools for specific downstream applications. They have the technical capability and experience to ...
R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...
GenScript is delighted to announce its 2nd Annual Virtual Summit on Gene and Cell Engineering. This gathering will feature leaders in the life sciences from academia, pharma, and biotech, leveraging ...
GenScript and Avectas agreed to partner to develop an improved non-viral cell therapy manufacturing process. By combining Avectas’ cell engineering technology with GenScript’s expertise in synthetic ...
Hello, and welcome to the GenScript Biotech Interim 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. It is now my pleasure to ...
GenScript is delighted to announce its 3rd Annual Virtual Summit on Gene and Cell Engineering. This gathering will feature leaders in the life sciences from academia, pharma, and biotech, leveraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results